Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

AN OPEN-LABEL, MULTICENTER PHASE I STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, PHARMACODYNAMICS, AND PRELIMINARY ANTI-TUMOR ACTIVITY OF ALPS12 IN PATIENTS WITH EXTENSIVE STAGE SMALL CELL LUNG CANCER

NCT07107490 is registered in ClinicalTrials.gov with Chugai Pharmaceutical as lead sponsor.

NCT NCT07107490
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07107490 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
AN OPEN-LABEL, MULTICENTER PHASE I STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, PHARMACODYNAMICS, AND PRELIMINARY ANTI-TUMOR ACTIVITY OF ALPS12 IN PATIENTS WITH EXTENSIVE STAGE SMALL CELL LUNG CANCER
Lead sponsor
Chugai Pharmaceutical
Phase
Phase 1
Overall status
Recruiting
Start date
October 8, 2025
Completion date
September 30, 2028
Enrollment
122 (estimated)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

extensive stage small cell lung cancer